Drug interactions should be evaluated in patients

Clinical Pharmacology and Therapeutics

Volumn 88, Issue 5, 2010, Pages 585-587

  Fletcher, C V ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR; DARUNAVIR; DIDANOSINE; EMTRICITABINE; ETRAVIRINE; LOPINAVIR PLUS RITONAVIR; MARAVIROC; RALTEGRAVIR; RIFABUTIN; RITONAVIR; SAQUINAVIR; TENOFOVIR; TIPRANAVIR;

ABSENCE OF SIDE EFFECTS; AREA UNDER THE CURVE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DESIGN; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEVER; GASTROINTESTINAL SYMPTOM; HEALTH CARE PERSONNEL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEUKOPENIA; LYMPHOCYTOPENIA; NOTE; PHARMACODYNAMICS; PREDICTION; PRIORITY JOURNAL; RASH; SIDE EFFECT; TREATMENT WITHDRAWAL; TUBERCULOSIS; VOLUNTEER; CLINICAL TRIAL (TOPIC); DRUG INTERACTION; EVIDENCE BASED MEDICINE; METHODOLOGY; PHARMACOKINETICS; PRACTICE GUIDELINE; RISK ASSESSMENT;

CLINICAL TRIALS AS TOPIC; DRUG INTERACTIONS; EVIDENCE-BASED MEDICINE; HUMANS; PHARMACOKINETICS; PRACTICE GUIDELINES AS TOPIC; RESEARCH DESIGN; RISK ASSESSMENT;

EID: 77958512004     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2010.213     Document Type: Note

References (10)

1. Dickinson, L., Khoo, S. & Back, D. Differences in the pharmacokinetics of protease inhibitors between healthy volunteers and HIV-infected persons. Curr. Opin. HIV AIDS 3, 296-305 (2008).
2. Fletcher, C.V. et al. Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials Group Study 359. J. Infect. Dis. 189, 1176-1184 (2004).
3. Wattanagoon, Y. et al. Pharmacokinetics of zidovudine phosphorylation in human immunodeficiency virus-positive Thai patients and healthy volunteers. Antimicrob. Agents Chemother. 44, 1986-1989 (2000).
4. Ng, J. et al. Pharmacokinetics of rifabutin 150 mg TIW plus lopinavir/ritonavir 400/100 BID administered in healthy adult subjects (abstr O21). 10th International Workshop on Clinical Pharmacology of HIV Therapy, Amsterdam, The Netherlands, 15-17 April 2009.
5. Boulanger, C. et al. Pharmacokinetic evaluation of rifabutin in combination with lopinavir-ritonavir in patients with HIV infection and active tuberculosis. Clin. Infect. Dis. 49, 1305-1311 (2009).
6. Kearney, B.P., Sayre, J.R., Flaherty, J.F., Chen, S.S., Kaul, S. & Cheng, A.K. Drug-drug and drug-food interactions between tenofovir disoproxil fumarate and didanosine. J. Clin. Pharmacol. 45, 1360-1367 (2005).
7. National Institutes of Health. Panel on Antiretroviral Guidelines for Adults and Adolescents: Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents (1 December 2009).
8. Brown, K.C., Paul, S. & Kashuba, A.D. Drug interactions with new and investigational antiretrovirals. Clin. Pharmacokinet. 48, 211-241 (2009)
9. Calcagno, A. et al. Pharmacokinetics of raltegravir, etravirine and maraviroc regimen in the clinical setting (abstr 59). 11th International Workshop on the Clinical Pharmacology of HIV Therapy, Sorrento, Italy, 7-9 April 2010.
10. Huang, S.M., Temple, R., Throckmorton, D.C. & Lesko, L.J. Drug interaction studies: study design, data analysis, and implications for dosing and labeling. Clin. Pharmacol. Ther. 81, 298-304 (2007).